المؤلفون: de la Rubia, Javier, González, Bernardo, Cruz-Jentoft, Alfonso J., Iglesias, Lorena, Pérez Persona, Ernesto, Gironella Mesa, Mercedes, Jarque, Isidro

المساهمون: Institut Català de la Salut, de la Rubia J, Jarque I Hematology Department, H.U. i Politècnic La Fe. Valencia, Spain. School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III. Madrid, Spain. González B Hematology Department, H.U. de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. Cruz-Jentoft AJ Geriatric Unit, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain. Iglesias L Hematology Department, C.H.U. A Coruña. A Coruña, Spain. Persona EP Hematology Department H. U, Vitoria-Gasteiz, Álava, Spain. Gironella M Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Persones grans, Sang - Malalties - Diagnòstic, Medicaments - Toxicologia, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Geriatric Assessment, PUBLIC HEALTH::Environmental Health::Science::Toxicology::Toxicity, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::evaluación geriátrica, SALUD PÚBLICA::salud ambiental::ciencia::toxicología::toxicidad

الوصف: Chemotherapy; Geriatric assessment; Toxicity ; Quimioterapia; Evaluación geriátrica; Toxicidad ; Quimioteràpia; Avaluació geriàtrica; Toxicitat ; Introduction The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at higher risk of treatment-related toxicity. Our objective in this study was to determine the weights for each dimension of the GAH scale and the cut-off point to reliably predict treatment tolerability in this population, estimated by a weighted receiver operating characteristic (ROC) analysis and quantified by the area under the curve (AUC). Material and Methods The RETROGAH was a retrospective cohort study including 126 patients who had previously participated in the GAH study. Patients were ≥ 65 years old with newly diagnosed myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), multiple myeloma (MM), or chronic lymphoid leukemia (CLL) and treated with standard front-line therapy within three months after having completed the GAH scale. Results The optimal cut-off value of the GAH total score to discriminate patients at higher risk of treatment toxicity was 42, with 68.5% sensitivity and 55.8% specificity. Using this value, 66.1% of patients evaluated were found to develop some type of toxicity. The AUC was 0.6259 (95% CI: 0.512–0.739; p = 0.035). Discussion The GAH scale not only would enable clinicians to individualize therapy based on individual risk of toxicity but also discriminate patients that will benefit most from intensive treatments from those requiring an adapted approach. While futures studies in clinical practice may improve the model and overcome its limitations, the GAH scale should not be used alone when making treatment decisions. ; This study was supported by Celgene España S.L.

وصف الملف: application/pdf

العلاقة: Journal of Geriatric Oncology;14(1); https://doi.org/10.1016/j.jgo.2022.10.016Test; de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, et al. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study. J Geriatr Oncol. 2023 Jan;14(1):101401.; https://hdl.handle.net/11351/9326Test; 000946209600001

الإتاحة: https://doi.org/10.1016/j.jgo.2022.10.016Test
https://hdl.handle.net/11351/9326Test

المؤلفون: Mohty, Mohamad, Terpos, Evangelos, Mateos, Maria-Victoria, Cavo, Michele, Lejniece, Sandra, Beksac, Meral, Bekadja, Mohamed Amine, Legiec, Wojciech, Dimopoulos, Meletios, Stankovic, Svetlana, Durán, Maria Soledad, De Stefano, Valerio, Corso, Alessandro, Kochkareva, Yulia, Laane, Edward, Berthou, Christian, Salwender, Hans, Masliak, Zvenyslava, Pečeliūnas, Valdas, Willenbacher, Wolfgang, Silva, João, Louw, Vernon, Nemet, Damir, Borbényi, Zita, Abadi, Uri, Pedersen, Robert Schou, Černelč, Peter, Potamianou, Anna, Couturier, Catherine, Feys, Caroline, Thoret-Bauchet, Florence, Boccadoro, Mario, Bekadja, Mohamed, Hamladji, Rose-Marie, Ali, Hocine Ait, Hamdi, Selma, Touhami, Hadj, Mansour, Nourredine Sidi, Linkesch, Werner, Pedersen, Robert Shou, Abildgaard, Niels, Hein, Marju, Eveillard, Jean Richard, Yamani, Abderrazak el, Moreau, Philippe, Sanhes, Laurence, Lepeu, Gérard, Laribi, Kamel, Jourdan, Eric, Fitoussi, Olivier, Allangba, Olivier, Fleury, Joël, Escoffre, Martine, Benramdane, Riad, Cartron, Guillaume, Dine, Gérard, Legouffe, Eric, Harich, Hanns-Detlev, Illmer, Thomas, Dörfel, Steffen, Hannig, Carla Verena, Koenigsmann, Michael, Prange-Krex, Gabriele, Tamm, Ingo, Zeller, Wolfgang, Maasberg, Michael, Schlag, Rudolf, Klausmann, Martine, Uhlig, Jens, Alkemper, Burkhard, Schütz, Stefan, Tessen, Hans-Werner, Mohr, Benno, Schmidt, Peter, Heinrich, Bernhard, Hebart, Holger, Seipelt, Gernot, Zoeller, Thomas, Heits, Frank, Müller-Naendrup, Clemens, Hansen, Richard, Repp, Roland, Von Weikersthal, Ludwig Fischer, Schmits, Rudolf, Heßling, Jörg, Krammer-Steiner, B., Janzen, Viktor, Schauer, Michael, Grüner, Marcus W., Kisro, Jens, Denzlinger, Claudio, Freier, Werner, Junghanss, Christian, Görner, Martin, Laichinger, Katharina, Ostermann, Helmut, Dürk, Heinz, Hess, Georg, Reich, Gernot, Matsouka, Panagiota, Pouli, Anastasia, Anagnostopoulos, Achilles, Masszi, Tamas, Ivanyi, Janos, Szomor, Arpad, Nagler, Arnon, Magen, Hila, Avivi, Irit, Quitt, Miriam, Palumbo, Antonio, Za, Tommaso, Vallisa, Daniele, Foa, Roberto, Bosi, Alberto, Vacca, Angelo, Lanza, Francesco, Palazzo, Giulia, Avvisati, Giuseppe, Ferrara, Felicetto, Consoli, Ugo, Cantonetti, Maria, Angelucci, Emanuele, Califano, Catello, Di Raimondo, Francesco, Guarini, Attilio, Musso, Maurizio, Pizzuti, Michele, Giuliani, Nicola, Ardizzoia, Antonio, Di Renzo, Nicola, Gaidano, Gianluca, Gozzetti, Alessandro, Pitini, Vincenzo, Farina, Gabriella, Centurioni, Riccardo, De Fabritiis, Paolo, Iuliano, Francesco, La Nasa, Giorgio, La Verde, Giacinto, Pane, Fabrizio, Recine, Umberto, La Targia, Maria, Mineo, Giuseppe, Cangialosi, Clotilde, Fagnani, Daniele, Federici, Augusto, Romano, Atelda, Specchia, Giorgina, Storti, Sergio, Bongarzoni, Velia, Bacigalupo, Andrea, Gobbi, Marco, Latte, Giancarlo, Mannina, Donato, Capalbo, Silvana, Jurgutis, Mindaugas, Woszczyk, Dariusz, Hołojda, Jadwiga, Gornik, Slawomir, Pluta, Andrzej, Morawiec-Szymonik, Elzbieta, Kyrcz-Krzemien, Slawomira, Homenda, Wojciech, Grosicki, Sebastian, Sulek, Kazimierz, Lange, Andrzej, Kloczko, Janusz, Starzak-Gwozdz, Jolanta, Hellmann, Andrzej, Komarnicki, Mieczyslaw, Kuliczkowski, Kazimierz, Viveiros, Carolina, Gonçalves, Cristina, Esefyeva, Natalia, Kochkareva, Julia, Kaplanov, Kamil, Volodicheva, Elena, Laricheva, Elena, Dergacheva, Valentina, Chukavina, Marina, Volchenko, Natalia, Nazarova, Irina, Anchukova, Ludmila, Ovanesova, Elena, Gritsenko, Taras, Salogub, Galina, Magomedova, Ludmila, Kuznetsova, Irina, Osyunikhina, Svetlana, Serdyuk, Olga, Karyagina, Elena, Ivanova, Valentina, Černelč, Slovenia Peter, Coetzee, Corlia, Gunther, Karen, Moodley, Dhayanithi, Duran, Soledad, Gutiérrez, Asunción Echeveste, De Oteyza, Jaime Perez, Capote, Francisco Javier, Casanova, Maria, Sanchez, Jesus Martin, Rios-Herranz, Eduardo, Ibañez-Garcia, Jeronima, Herranz, Maria Jose, Hernandez, Belen, Sanchez, Sara Sanchez, Escalante, Fernando, Carnicero, Fernando, Lleonart, Joan Bargay, Gironella, Mercedes, Martínez, Rafael, De La Guia, Ana Lopez, Palomera, Luis, Iglesias, Rebeca, Ramos, Fernando Solano, De La Serna, Javier, Sanchez, Pedro Garcia, Vidal, Juan Besalduch, Morfa, Miguel Diaz, Beksac, Turkey – Meral, Vural, Filiz, Aydin, Yildiz, Unal, Ali, Goker, Hakan, Bilgir, Oktay, Guvenc, Birol, Turgut, Mehmet, Ozet, Gulsum Gulistan, Ali, Ridvan, Kyselyova, Maryna, Glushko, Nataliia, Vybyrana, Renata, Skrypnyk, Igor, Tretyak, Natalya, Kharchevska, Tetiana, Dyagil, Iryna, Popovs'ka, Tetiana, Shimanskiy, Vadim, Lysa, Tamila, Oliynyk, Hanna, Vilchevskaya, Kateryna, Kryachok, Iryna, Popovych, Yuriy, Romanyuk, Natalia, Yushchenko, Natalia, Kaplan, Polina, Rekhtman, Grygoriy, Pylypenko, Halyna, Kozlov, Viktor, Drach, Johannes, Harousseau, Jean-Luc, Einsele, Hermann, Goldschmidt, Hartmut, Facon, Thierry, Michalet, Mauricette, Savchenko, Valery G., De la Rubia, Javier, Cook, Gordon, Mellqvist, Ulf-Henrik, Ludwig, Heinz

الوصف: BACKGROUND: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. --- PATIENTS AND METHODS: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. --- RESULTS: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. --- CONCLUSION: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This ...

وصف الملف: application/pdf

العلاقة: http://medlib.mef.hr/3355/1/mohty_m_rep_3355.pdfTest; Mohty, Mohamad and Terpos, Evangelos and Mateos, Maria-Victoria and Cavo, Michele and Lejniece, Sandra and Beksac, Meral and Bekadja, Mohamed Amine and Legiec, Wojciech and Dimopoulos, Meletios and Stankovic, Svetlana and Durán, Maria Soledad and De Stefano, Valerio and Corso, Alessandro and Kochkareva, Yulia and Laane, Edward and Berthou, Christian and Salwender, Hans and Masliak, Zvenyslava and Pečeliūnas, Valdas and Willenbacher, Wolfgang and Silva, João and Louw, Vernon and Nemet, Damir and Borbényi, Zita and Abadi, Uri and Pedersen, Robert Schou and Černelč, Peter and Potamianou, Anna and Couturier, Catherine and Feys, Caroline and Thoret-Bauchet, Florence and Boccadoro, Mario and Bekadja, Mohamed and Hamladji, Rose-Marie and Ali, Hocine Ait and Hamdi, Selma and Touhami, Hadj and Mansour, Nourredine Sidi and Willenbacher, Wolfgang and Linkesch, Werner and Nemet, Damir and Pedersen, Robert Shou and Abildgaard, Niels and Laane, Edward and Hein, Marju and Mohty, Mohamad and Eveillard, Jean Richard and Yamani, Abderrazak el and Moreau, Philippe and Sanhes, Laurence and Lepeu, Gérard and Laribi, Kamel and Jourdan, Eric and Fitoussi, Olivier and Allangba, Olivier and Fleury, Joël and Escoffre, Martine and Benramdane, Riad and Cartron, Guillaume and Dine, Gérard and Legouffe, Eric and Harich, Hanns-Detlev and Illmer, Thomas and Dörfel, Steffen and Hannig, Carla Verena and Koenigsmann, Michael and Prange-Krex, Gabriele and Salwender, Hans and Tamm, Ingo and Zeller, Wolfgang and Maasberg, Michael and Schlag, Rudolf and Klausmann, Martine and Uhlig, Jens and Alkemper, Burkhard and Schütz, Stefan and Tessen, Hans-Werner and Mohr, Benno and Schmidt, Peter and Heinrich, Bernhard and Hebart, Holger and Seipelt, Gernot and Zoeller, Thomas and Heits, Frank and Müller-Naendrup, Clemens and Hansen, Richard and Repp, Roland and Von Weikersthal, Ludwig Fischer and Schmits, Rudolf and Heßling, Jörg and Krammer-Steiner, B. and Janzen, Viktor and Schauer, Michael and Grüner, Marcus W. and Kisro, Jens and Denzlinger, Claudio and Freier, Werner and Junghanss, Christian and Görner, Martin and Laichinger, Katharina and Ostermann, Helmut and Dürk, Heinz and Hess, Georg and Reich, Gernot and Terpos, Evangelos and Dimopoulos, Meletios and Matsouka, Panagiota and Pouli, Anastasia and Anagnostopoulos, Achilles and Masszi, Tamas and Borbényi, Zita and Ivanyi, Janos and Szomor, Arpad and Abadi, Uri and Nagler, Arnon and Magen, Hila and Avivi, Irit and Quitt, Miriam and Palumbo, Antonio and Boccadoro, Mario and De Stefano, Valerio and Za, Tommaso and Vallisa, Daniele and Foa, Roberto and Corso, Alessandro and Bosi, Alberto and Vacca, Angelo and Lanza, Francesco and Palazzo, Giulia and Avvisati, Giuseppe and Cavo, Michele and Ferrara, Felicetto and Consoli, Ugo and Cantonetti, Maria and Angelucci, Emanuele and Califano, Catello and Di Raimondo, Francesco and Guarini, Attilio and Musso, Maurizio and Pizzuti, Michele and Giuliani, Nicola and Ardizzoia, Antonio and Di Renzo, Nicola and Gaidano, Gianluca and Gozzetti, Alessandro and Pitini, Vincenzo and Farina, Gabriella and Centurioni, Riccardo and De Fabritiis, Paolo and Iuliano, Francesco and La Nasa, Giorgio and La Verde, Giacinto and Pane, Fabrizio and Recine, Umberto and La Targia, Maria and Mineo, Giuseppe and Cangialosi, Clotilde and Fagnani, Daniele and Federici, Augusto and Romano, Atelda and Specchia, Giorgina and Storti, Sergio and Bongarzoni, Velia and Bacigalupo, Andrea and Gobbi, Marco and Latte, Giancarlo and Mannina, Donato and Capalbo, Silvana and Lejniece, Sandra and Pečeliūnas, Valdas and Jurgutis, Mindaugas and Stankovic, Svetlana and Legiec, Wojciech and Woszczyk, Dariusz and Hołojda, Jadwiga and Gornik, Slawomir and Pluta, Andrzej and Morawiec-Szymonik, Elzbieta and Kyrcz-Krzemien, Slawomira and Homenda, Wojciech and Grosicki, Sebastian and Sulek, Kazimierz and Lange, Andrzej and Kloczko, Janusz and Starzak-Gwozdz, Jolanta and Hellmann, Andrzej and Komarnicki, Mieczyslaw and Kuliczkowski, Kazimierz and Viveiros, Carolina and Gonçalves, Cristina and Esefyeva, Natalia and Kochkareva, Julia and Kaplanov, Kamil and Volodicheva, Elena and Laricheva, Elena and Dergacheva, Valentina and Chukavina, Marina and Volchenko, Natalia and Nazarova, Irina and Anchukova, Ludmila and Ovanesova, Elena and Gritsenko, Taras and Salogub, Galina and Magomedova, Ludmila and Kuznetsova, Irina and Osyunikhina, Svetlana and Serdyuk, Olga and Karyagina, Elena and Ivanova, Valentina and Černelč, Slovenia Peter and Louw, Vernon and Coetzee, Corlia and Gunther, Karen and Moodley, Dhayanithi and Duran, Soledad and Gutiérrez, Asunción Echeveste and De Oteyza, Jaime Perez and Capote, Francisco Javier and Casanova, Maria and Sanchez, Jesus Martin and Rios-Herranz, Eduardo and Ibañez-Garcia, Jeronima and Herranz, Maria Jose and Hernandez, Belen and Sanchez, Sara Sanchez and Escalante, Fernando and Carnicero, Fernando and Lleonart, Joan Bargay and Gironella, Mercedes and Martínez, Rafael and De La Guia, Ana Lopez and Palomera, Luis and Iglesias, Rebeca and Ramos, Fernando Solano and De La Serna, Javier and Sanchez, Pedro Garcia and Vidal, Juan Besalduch and Mateos, Maria-Victoria and Morfa, Miguel Diaz and Beksac, Turkey – Meral and Vural, Filiz and Aydin, Yildiz and Unal, Ali and Goker, Hakan and Bilgir, Oktay and Guvenc, Birol and Turgut, Mehmet and Ozet, Gulsum Gulistan and Ali, Ridvan and Masliak, Zvenyslava and Kyselyova, Maryna and Glushko, Nataliia and Vybyrana, Renata and Skrypnyk, Igor and Tretyak, Natalya and Kharchevska, Tetiana and Dyagil, Iryna and Popovs'ka, Tetiana and Shimanskiy, Vadim and Lysa, Tamila and Oliynyk, Hanna and Vilchevskaya, Kateryna and Kryachok, Iryna and Popovych, Yuriy and Romanyuk, Natalia and Yushchenko, Natalia and Kaplan, Polina and Rekhtman, Grygoriy and Pylypenko, Halyna and Kozlov, Viktor and Mohty, Mohamad and Terpos, Evangelos and Mateos, Maria-Victoria and Palumbo, Antonio and Drach, Johannes and Boccadoro, Mario and Harousseau, Jean-Luc and Einsele, Hermann and Goldschmidt, Hartmut and Facon, Thierry and Michalet, Mauricette and Savchenko, Valery G. and De la Rubia, Javier and Cook, Gordon and Mellqvist, Ulf-Henrik and Ludwig, Heinz (2018) Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clinical Lymphoma Myeloma and Leukemia, 18 (10). e401-e419. ISSN 2152-2650

الإتاحة: https://doi.org/10.1016/j.clml.2018.06.018Test
http://medlib.mef.hr/3355Test/
http://medlib.mef.hr/3355/1/mohty_m_rep_3355.pdfTest

المؤلفون: Giralt, Sergio, Garderet, Laurent, Durie, Brian, Cook, Gordon, Gahrton, Gosta, Bruno, Benedetto, Hari, Paremesweran, Lokhorst, Henk, McCarthy, Phillip, Krishnan, Amrita, Sonneveld, Pieter, Goldschmidt, Harmut, Jagannath, Sundar, Barlogie, Bart, Mateos, Maria, Gimsing, Peter, Sezer, Orhan, Mikhael, Joseph, Lu, Jin, Dimopoulos, Meletios, Mazumder, Amitabha, Palumbo, Antonio, Abonour, Rafat, Anderson, Kenneth, Attal, Michel, Blade, Joan, Bird, Jenny, Cavo, Michele, Comenzo, Raymond, de la Rubia, Javier, Einsele, Hermann, Garcia-Sanz, Ramon, Hillengass, Jens, Holstein, Sarah, Johnsen, Han, Joshua, Douglas, Koehne, Guenther, Kumar, Shaji, Kyle, Robert, Leleu, Xavier, Lonial, Sagar, Ludwig, Heinz, Nahi, Hareth, Nooka, Anil, Orlowski, Robert, Rajkumar, Vincent, Reiman, Anthony, Richardson, Paul, Rivas, Eloisa, San Miguel, Jesus, Turesson, Ingemar, Usmani, Saad, Vesole, David, Bensinger, William, Qazilbash, Muzaffer, Efebera, Yvonne, Mohty, Mohamed, Gasparreto, Christina, Gajewski, James, LeMaistre, Charles F, Bredeson, Chris, Moreau, Phillipe, Pasquini, Marcelo, Kroeger, Nicolaus, Stadtmauer, Edward

المصدر: Biology of Blood and Marrow Transplantation; 21(12), pp 2039-2051 (2015) ; ISSN: 1083-8791

مصطلحات موضوعية: Hematology

الوصف: In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward. After reviewing the available data, the expert committee came to the following consensus statement for salvage autologous HCT: (1) In transplantation-eligible patients relapsing after primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard; (2) High-dose therapy and autologous HCT should be considered appropriate therapy for any patients relapsing after primary therapy that includes an autologous HCT with initial remission duration of more than 18 months; (3) High-dose therapy and autologous HCT can be used as a bridging strategy to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in the context of well-designed prospective trials that should include new agents, such as monoclonal antibodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous HCT consolidation should be explored as a strategy to develop novel conditioning regimens or post-HCT strategies in patients with short (less than 18 months remissions) after primary ...

العلاقة: https://lup.lub.lu.se/record/8159133Test; http://dx.doi.org/10.1016/j.bbmt.2015.09.016Test; pmid:26428082; wos:000364981700003; scopus:84947430469

الإتاحة: https://doi.org/10.1016/j.bbmt.2015.09.016Test
https://lup.lub.lu.se/record/8159133Test